Danielle S. McDermott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Danielle S. McDermott has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alison M. Hixon
Division of Infectious Disease, Washington University
1 shared publication - Aviva Abosch
Baptist Health Miami Neuroscience Institute, Miami, FL, USA
1 shared publication - Cornelia Drees
Mayo Clinic Phoenix Arizona USA
1 shared publication - David E. Burdette
Department of Neurosciences, Corewell Health and Michigan State University College of Human Medicine, Grand Rapids, MI 49503, USA
1 shared publication Emily A. Johnson
Washington University School of Medicine St. Louis MO USA
1 shared publication- Emily A. Mirro
NeuroPace, Inc
1 shared publication
Latest Publications
- Open Access
- 27 February 2021
- Published by Wiley in Epilepsia Open
- Vol. 6 (2) , 419-424
Brain‐Responsive Neurostimulation for the treatment of adults with epilepsy in tuberous sclerosis complex: A case series
Objective: Tuberous sclerosis complex (TSC) is a genetic disorder primarily characterized by the development of multisystem benign tumors. Epilepsy is the most common neurologic manifestation, affecting 80%‐90% of TSC patients. The diffuse structural brain abnormalities and the multifocal nature of epilepsy in TSC pose diagnostic challenges when evaluating patients for epilepsy surgery.Methods: We retrospectively reviewed the safety experience and efficacy outcomes of five adult TSC patients who were treated with direct brain‐responsive neurostimulation (RNS System, NeuroPace, Inc).Results: The average follow‐up duration was 20 months. All five patients were responders (≥50% disabling seizure reduction) at last follow‐up. The median reduction in disabling seizures was 58% at 1 year and 88% at last follow‐up. Three of the five patients experienced some period of seizure freedom ranging from 3 months to over 1 year.Significance: In this small case series, we report the first safety experience and efficacy outcomes in patients with TSC‐associated drug‐resistant focal epilepsy treated with direct brain‐responsive neurostimulation.
- 27 February 2021
- Published by Wiley in Epilepsia Open
- Vol. 6 (2) , 419-424
Open AccessBrain‐Responsive Neurostimulation for the treatment of adults with epilepsy in tuberous sclerosis complex: A case series
Objective: Tuberous sclerosis complex (TSC) is a genetic disorder primarily characterized by the development of multisystem benign tumors. Epilepsy is the most common neurologic manifestation, affecting 80%‐90% of TSC patients. The diffuse structural brain abnormalities and the multifocal nature of epilepsy in TSC pose diagnostic challenges when evaluating patients for epilepsy surgery.Methods: We retrospectively reviewed the safety experience and efficacy outcomes of five adult TSC patients who were treated with direct brain‐responsive neurostimulation (RNS System, NeuroPace, Inc).Results: The average follow‐up duration was 20 months. All five patients were responders (≥50% disabling seizure reduction) at last follow‐up. The median reduction in disabling seizures was 58% at 1 year and 88% at last follow‐up. Three of the five patients experienced some period of seizure freedom ranging from 3 months to over 1 year.Significance: In this small case series, we report the first safety experience and efficacy outcomes in patients with TSC‐associated drug‐resistant focal epilepsy treated with direct brain‐responsive neurostimulation.
- 24 July 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 112, 107327
RNS modifications to eliminate stimulation-triggered signs or symptoms (STS): Case series and practical guide
- 24 July 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 112, 107327
RNS modifications to eliminate stimulation-triggered signs or symptoms (STS): Case series and practical guide